Allogenic CD19-targeting CAR-γδT Cell Therapy in R/R NHL

Clinical trial NCT05554939 · RECRUITING

Trial details

NCT number: NCT05554939
Sponsor: Chinese PLA General Hospital
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Non Hodgkin's Lymphoma

Start date: 2022-12-11
Primary completion: 2026-12-31
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.